CClinicalTrials.gg
CompletedNCT00878787Updated May 30, 2014

Theta-burst Transcranial Magnetic Stimulation

An interventional study of Transcranial magnetic stimulation in Dystonia, sponsored by University of Southern California. Completed at 1 site in United States. Open to participants aged 2 Years to 29 Years. Per ClinicalTrials.gov, last updated 2014-05-30.

Sponsored by University of Southern California · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
2 Years to 29 Years
Sex
All
01

Study summary

Theta-burst transcranial magnetic stimulation (TBS) is a type of repetitive transcranial magnetic stimulation (rTMS) method that reduces the excitability of a small region of brain for less than one hour. Since dystonia and spasticity may be associated with increased excitability of motor cortex, we expect that by reducing the excitability of motor cortex with TBS we will temporarily improve these symptoms and hopefully open avenues in the future for the use of TBS as a new, non-invasive therapeutic intervention to aid in physical therapy and symptom amelioration of dystonia and spasticity. We will test for motor improvement during the hour immediately following TBS using tests of muscle function and quality of limb movement.

Read the detailed description

Testing will occur at three identical visits, with escalating stimulation intensity at each visit. Initial screening will be performed by telephone or in clinic and final screening will be performed and informed consent will be signed at the start of the first study visit. Initial set-up and calibration of the magnetic stimulation device will require 10-20 minutes. Theta-burst stimulation requires 40 seconds. Hand and arm function will be tested immediately before and during the one hour following the TBS. Therefore, each visit should occupy 90-120 minutes. Each visit will be at least 2 days after the previous visit and a telephone call will be placed one week after the third visit.

Testing of limb function will be performed according to standard clinical rating scales, including the modified Ashworth spasticity scale and the Barry-Albright Dystonia rating scale. Electrophysiological testing of hand function will involve moving finger muscles against resistance while surface electromyographic signals (EMG) are monitored for the ability to activate one finger at a time while minimizing muscle co-contraction and overflow. Testing of arm function will involve measurement of the ability to relax the biceps and triceps and the resistance of the elbow to passive movement by the examiner.

Testing of cortical function will occur both before and after theta-burst stimulation, and will involve a standard protocol using suprathreshold single and paired-pulse magnetic stimulation with measurement of the induced motor evoked potential (MEP) in the hand and arm muscles. The resting MEP threshold and input-output curve will be measured for the first dorsal interosseus muscle. Paired-pulse inhibition of the MEP will be tested using a subthreshold pulse (80% of resting motor threshold) followed by a suprathreshold pulse at 2.5msec interval. Paired-pulse facilitation will be tested using a 12msec interval. Silent period duration in response to a pulse at 120% of resting motor threshold will be measured.

Theta-burst stimulation will be performed according to the standard protocols developed by Rothwell and co-workers with NIH and European consortium safety guidelines stringently enforced. Active motor threshold and resting motor threshold will be determined by single-pulse stimulation while monitoring electromyographic (EMG) activity at the first dorsal interosseus (FDI) muscle according to standard published protocols using commercially available surface EMG electrodes (DelSys Inc.). Stimulation will be performed using the commercially-available Magstim Rapid 2 (Magstim, Inc., Wales UK) with a standard figure-eight coil held by a member of the research team. Biphasic stimulation pulses will be given according to the standard included driver software. Single pulse, paired pulse, and theta-burst rapid stimulation protocols are directly available through standard user options on this device.

Threshold determination and stimulation location will be performed using each subject's most affected hand, or the non-dominant hand if both hands are affected. The location of lowest threshold for stimulation of the FDI will be determined by gradual movement of the stimulation coil over the surface of the contralateral scalp, in the region of the standard "C3" or "C4" electrode position (determined by international 10-20 EEG electrode placement convention). The handle of the stimulation coil will be pointed backward and 45 degrees from the sagittal plane so as to be approximately perpendicular to the rolandic fissure. The location of minimum threshold will be marked with a washable non-permanent marker on the subject's scalp in order to ensure consistency of stimulation.

For assessment of active motor threshold, subjects will be asked to contract the FDI muscle against resistance while being given biofeedback to maintain average integrated EMG at 20% of maximal voluntary isometric EMG. For assessment of resting motor threshold, EMG of the FDI must be less than 5% of maximal prior to stimulation. Single-pulses at increasing intensity will be used to determine the intensity at which 5 out of 10 pulses evoke an EMG response greater than 200mV (active threshold) or 50mV (resting threshold) above baseline. (Active motor threshold is virtually always less than the resting motor threshold. If this is not the case in a subject, then stimulation will be adjusted so that intensity never exceeds 80% of the resting motor threshold.) Thresholds will be assessed both before and after theta-burst stimulation, and these thresholds will be used for the cortical excitability testing as described above.

Stimulation intensity for theta burst will be set at 60% active motor threshold (visit 1), 80% active motor threshold (visit 2), and 80% resting motor threshold (visit 3). All stimulation is subthreshold, and thus not expected to produce muscle activity. To ensure this is the case, muscle activity will be continuously monitored from the FDI and stimulation will be aborted if any muscle activity during the TBS is detected.

Set-up of theta-burst stimulation will involve the same Magstim Rapid 2 device in which the handle of the stimulation coil (same standard figure-eight coil) will be pointed backward and 45 degrees from the sagittal plane so as to be approximately perpendicular to the rolandic fissure. We will use a continuous (cTBS) pattern of delivery for magnetic stimulation and pulses will occur in sets of three at 20msec intervals (50hz burst rate), with each burst of three pulses separated by 200msec (5hz inter-burst rate). Thus there are 15 pulses per second, divided into 5 bursts of three pulses. Each burst of three pulses will be the same. Stimulation will continue for 40 seconds, for a total of 600 pulses. The subject will be instructed to maintain all muscles relaxed, and relaxation relevant to stimulation will be monitored using EMG of the FDI muscle. After the initial TBS treatment, single and paired-pulse magnetic stimulation will be performed again to test cortical function and MEP threshold. These pulses will be applied in the same manner as before TBS treatment (described in previous paragraph).

The stimulation pulses can produce a loud clicking noise, and subjects will be provided with earplugs or sound isolating ear cuffs if the sound intensity becomes uncomfortable or exceeds normal speech volume.

02

Conditions studied

  • Dystonia
03

In context

Dystonia

319 studies on the registry are indexed under Dystonia; 56 are open to participants now.

This study's enrollment of 5 is below the median of 32 across 181 interventional studies indexed under Dystonia.

Browse Dystonia studies →

Lead sponsor

University of Southern California is the lead sponsor of 773 studies on the registry; 135 are open to participants now.

Of its 68 completed or terminated interventional studies of FDA-regulated products, 32 (47%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 29 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:1. Dystonia affecting one or both hands or arms, and/or spasticity affecting one or both hands/arms 2. Age 2 years to 29 years 3. Sufficient cognitive function to attempt isolated finger movements Exclusion Criteria:1. any metallic implants in the head or neck 2. seizure within 2 years of study entry, or prior history of status epilepticus outside the newborn period.

  1. deep-brain stimulator, vagal nerve stimulator, pacemaker, intrathecal baclofen pump, or other implanted electrical device.
  1. prior neurosurgical procedure 5. migraine disorder 6. known cardiac arrhythmia, or history of syncope 7. use of tricyclic antidepressants or neuroleptic medications during the study 8. use or requirement for medications to treat seizures
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Theta-burst Trancranial Magnetic Stim

    Device: Transcranial magnetic stimulation

Interventions

  • DeviceTranscranial magnetic stimulation
06

What researchers measure

Primary outcomes

  1. surface EMG overflow and control

    Time frame: 1 hour

07

Study locations

1 site
  • Stanford University School of Medicine
    Stanford, California 94305, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00878787
Lead sponsor
University of Southern California
Responsible party
Terence Sanger (Associate Professor, University of Southern California) — Principal investigator
First posted
Apr 9, 2009
Start date
Jan 2008
Primary completion
Jan 2010
Completion
Jan 2010
Last update
May 30, 2014

Study contacts

Terence D. Sanger
principal investigator · Stanford University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion